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EXECUTIVE SUMMARY 
As the world population continues to age, so will the number of people with dementia continue to rise
rapidly. This growing prevalence poses many challenges, including the economic challenge of how societies
can ensure that treatment, care and support are provided at an aﬀordable cost, whilst ensuring good quality
of life for people with dementia and their families. The aim of this research is to examine the economic
consequences of diﬀerent ways to respond to this challenge.
We start with a fully costed description of care and support for people with dementia in the UK today, with
which we then compare four alternative scenarios. Two of these scenarios represent arrangements that are
worse than today, and two of them better. We use simulation modelling to compare these scenarios: our
aggregate model estimates the overall cost and quality of life consequences over one year for the UK; and our
illustrative lifetime model estimates the cost and quality of life impacts for a ‘typical’ individual from the point
of onset of dementia until death.
Data to populate the models are taken from various UK and other sources, including epidemiological studies,
descriptions of care and support patterns, randomised trials of specific interventions and expert opinion.
Included in these sources are individual-level data from a dozen recent UK dementia trials and observational
studies. Costs include both public expenditure and wider societal costs; we separate health, social care and
unpaid (informal) carer costs. Outcomes are measured as gains in quality-adjusted life years (QALYs) by
people with dementia. Although we are not able to measure quality of life changes for carers in our
quantitative modelling, we comment on the likely impacts of diﬀerent scenarios on carers where relevant.
Our new analyses suggest that the annual cost of dementia in the UK in 2015 (as measured for the purposes
of these analyses) will be approximately £21 billion (at 2012/13 price levels). More than a third of this total is
the (imputed) cost of unpaid care provided by family and other carers. The total divides into 20% health care
costs, 45% social care costs (publicly and privately funded) and 35% unpaid care costs. Dementia also has
major impacts for the quality of life of both the estimated 800,000 people with dementia in the UK in 2015
and their carers. This current care scenario provides the baseline against which we compare the other four
scenarios. 
The no-diagnosis scenario describes a situation where no one with dementia has their condition diagnosed,
and no dementia-specific services are delivered. We are able to look only at the consequences of not having
medications which alleviate the symptoms of dementia, and of not having community-based social care
support for dementia. Other potential impacts of not diagnosing dementia include higher risk of crises, such
as emergency hospital admission resulting from a fall, but we are not able to model these impacts. For this
no-diagnosis scenario we find that the overall costs would be around £350 million higher than today’s care
and support arrangements, and outcomes would be slightly lower. 
The diagnosis-only scenario occurs when people with dementia do get a diagnosis but then receive no
dementia-specific post-diagnostic support. Our modelling was the same as for the no-diagnosis scenario
except that now we need include the cost of carrying out a diagnosis. Overall costs would be £500 million
higher than they are currently, and again outcomes would be worse. 
Neither the no-diagnosis nor the diagnosis-only scenario could be seen as better than current arrangements
in the UK. Two other scenarios are explored in anticipation that they would be better than current
arrangements. The improved care scenario assumes that everyone with dementia will have their disorder
diagnosed, treated and supported with interventions that have been shown through well-conducted
research to be more eﬀective and/or cost-eﬀective than standard care. Four specific variants of ‘improved’
care are modelled:
• If medications to alleviate the symptoms of dementia are available to everyone with Alzheimer’s disease,
the eﬀect would to save around £250 million in overall costs, comprising a saving of about £400 million
in social care with a partially oﬀsetting extra cost of £150 million for unpaid care. 
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• If cognitive stimulation therapy is delivered to everyone with mild or moderate dementia, there would be
little diﬀerence in overall costs, with a slight shift from social care to health care costs. 
• If case management is used to coordinate care then this would increase overall costs by around £225
million, comprising a saving of around £1.15 billion on health and social care costs but an increase of
almost £1.4 billion in the imputed costs of unpaid care.
• Finally, if family carers of people with dementia were supported with a coping intervention then overall
costs would be around £200 million higher than they are today, comprising a saving of £200 million on
health and social care and increase of £400 million in unpaid care costs. There would however be
significant improvements in carer quality of life.
We are not able to model what would happen if these improved interventions are delivered as a combined
package of care (the ‘stacking’ assumption), because no studies have shown what the cumulative eﬀects
might be. Nevertheless, there is clearly a strong economic case emerging for improved care and support
shown by these simple models, with cost savings and/or quality of life improvements.
Disease-modifying treatments are not yet available for dementia. We examine a number of purely
hypothetical (but, we hope, plausible) variants. The economic case for such treatments will depend crucially
on assumptions made about how and when the course of the disease is altered.
• We look first at a treatment that slows progression, but with life expectancy unchanged. People diagnosed
with dementia receive treatment which prolongs time in both the mild and moderate cognitive
impairment states by 10%, but with no extension in life expectancy (which implies a higher mortality rate
than is currently observed in the severe state). This scenario would save the UK almost £0.8 billion per
year if available today (equivalent to 4% of today’s costs). 375,000 people with dementia and their carers
would benefit.
• A variant of this approach assumes slows progression and an improvement in life expectancy. As with the
previous variant, people diagnosed with dementia receive treatment which prolongs time in both the
mild and moderate cognitive impairment states by 10% and increases life expectancy (through no rise in
mortality rate in the severe state). The number of people with dementia would be 870,000 rather than
800,000, the cost would be £1,725 million higher and outcomes would be rather higher than under
current patterns of care.
• A further variant slows progression, reduces needs and improves life expectancy. People diagnosed with
dementia receive treatment which prolongs time in both the mild and moderate cognitive impairment
states by 10%, reduces need and average weekly costs in those states by 13.5%, and increases life
expectancy. The number of people with dementia would again be 870,000 rather than 800,000, the cost
would now be only £125 million higher than today’s arrangements, but outcomes (quality-adjusted life
years gained) would be considerably higher.
• We also look at a disease-modifying treatment that delays dementia onset. If this was available for
everyone and delayed onset by 12 months, with disease progression then running the same course as
today, it would save the UK around £1.5 billion per year if available today (equivalent to 7% of today’s
costs). Around 800,000 people with dementia and their carers would benefit from the delayed onset.
• A variant of this approach assumes delayed onset for as long as 36 months. This could save the UK as much
as £4.9 billion per year (23% of today’s costs). Again 800,000 people with dementia and their carers would
benefit from the delayed onset.
We must emphasise that all the figures in this report are indicative estimates. Every one of the scenarios
examined required us to make numerous assumptions. The hypothetical nature of the disease-modifying
scenarios makes their estimated impacts particularly uncertain. 
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Evidence-based care and support interventions are available today that can improve the quality of life of
older people with dementia and their carers. They would not be particularly costly to oﬀer to more people
than currently receive them, and there would be important outcome gains. Targeting of these interventions
could improve their eﬀectiveness and cost-eﬀectiveness.
However, to reduce the costs of care and support in more than relatively modest ways requires the
development of new interventions. A treatment that delayed the progression of dementia from the mild to
the moderate and severe stages could reduce, or at least slow the increase in, numbers of people with
dementia and/or increase overall survival with dementia, and could lead to marked cost reductions. 
A two-pronged response to the economic challenge of dementia is needed. We must continue to invest in
treatment, care and support services that can improve the lives of people with dementia and their carers.
And we must continue to search for disease-modifying treatments. The latter strategy oﬀers the best hope for
an aﬀordable and eﬀective response to rapidly growing global needs.
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1. INTRODUCTION
The growing number of people with dementia is both a huge global achievement and a growing global
challenge. In most high-income countries, the combination of mid-Twentieth Century baby booms, public
health initiatives and treatment breakthroughs have combined to produce a rapidly growing ‘older’
population. Population ageing is even faster in many low- and middle-income countries. Changes in
technology, information and social structures over the past 100 years or more have also combined to give
each successive generation yet higher expectations for living standards, and therefore also for what they
have come to expect from health and social care systems.
The scientific, social and economic successes of recent decades should be celebrated for considerably
extending life expectancy in most countries. At the same time, these successes have led to substantial
increases in the prevalence of age-related conditions such as dementia. The growing prevalence of dementia
poses challenges, including the economic challenge of how societies can ensure that treatment, care and
support needed by individuals with dementia and their carers is provided at reasonable cost. Governments
across the globe are urgently looking for aﬀordable responses to the dementia challenge, whilst ensuring
good quality of life for those people aﬀected.
We report research conducted over the past 3 months which investigated the economic consequences of five
diﬀerent scenarios for dementia. The first scenario – and the baseline from which we make comparisons with
the other scenarios – is the system of care and support for people with dementia in the UK today, including
the current situation where only about half of all people with dementia have had their illness diagnosed. We
compare today’s arrangements with four scenarios. Two of these alternative scenarios represent
arrangements that are likely to be seen as worse than the situation today: no diagnosis, and no post-
diagnostic support. 
The other two scenarios are assumed to be better than today’s arrangements. In one, we examine what would
happen if everyone with dementia is given ‘improved’ care and support in the sense that the services
provided have been shown through well-conducted research to deliver better outcomes and/or lower costs.
We explore four variants to illustrate this ‘improved’ scenario, linked to better access to medications that
alleviate the symptoms of dementia, psychosocial therapy, case management and support for family carers.
The other scenario is more hypothetical: it assumes the availability of a disease-modifying treatment,
although of course none has yet been developed or delivered anywhere across the world. We look at two
main variants of this scenario, one which delays the onset of dementia and the other which slows its
progression, and make diﬀerent assumptions about life expectancy and support costs. 
For each of these five scenarios we endeavour to estimate both the cost implications – by tracing through the
eﬀects on patterns of treatment, care and support, including from unpaid family and other carers – and the
impact on health-related quality of life. 
It must be emphasised that our estimates can only be indicative. None of the scenarios that we have looked
at has previously been studied in a way that would easily generate evidence that would allow economic
comparisons to be drawn; indeed, one of the scenarios is completely hypothetical. Our approach is therefore
to simulate what would be likely to result (in terms of cost and quality of life) on the basis of available
evidence from epidemiological, clinical and economic studies, and from administrative databases.
In the next section we set out our research aims, then in Section 3 describe our methods (the structure of our
simulation models, the sources of data used to populate those models, and the ways in which we calculated
prevalence, balance of care, costs and health-related quality of life). We follow that with a section on how we
operationalise the various scenarios, converting evidence from epidemiological sources and trials so that cost
and quality of life calculations can be made. In Section 5 we present our results, applying our models to each
of the scenarios and their variants. Our final section draws some brief conclusions.
Scenarios of dementia care: what are the impacts on cost and quality of life
4
2. RESEARCH AIMS
Earlier this year, we were commissioned by the Department of Health for England to compare the economic
consequences of four dementia care ‘scenarios’ (which we label B to E below) with current arrangements
(labelled scenario A below):
Current care scenario: People with dementia and their carers receive care and support as currently provided
in England (Scenario A). 
No-diagnosis scenario: People with dementia do not have their condition diagnosed and so do not receive
dementia-specific care (Scenario B). 
Diagnosis-only scenario: People with dementia receive a diagnosis but get no (dementia-specific) post-
diagnostic formal care or treatment (Scenario C).
Improved care scenario: People with dementia receive a diagnosis, followed by evidence-based, ‘improved’
care and support, where ‘improvements’ have been demonstrated in robust trials (Scenario D). 
Disease-modifying scenario: One or more disease-modifying treatment or therapy is available that either
slows the progression of dementia or delays its onset (Scenario E).
As we describe below, most of these scenarios have more than one interpretation (or ‘variant’). 
Our interpretation of ‘economic consequences’ is to measure as wide a range of costs as possible – and
certainly to include the costs of unpaid care by family and other carers – and to assess health-related quality
of life in a way that allows us to assess the impact on quality-adjusted life years. We give more explanation of
these components in the next section. Our quantitative estimates of health-related quality of life relate
mainly to people with dementia, although we do also discuss possible impacts on their (unpaid) carers where
the available evidence allows.
Our calculations of the comparative impacts of these various scenarios are grossed up to the UK as a whole.
Treatment and care arrangements are broadly not very diﬀerent across the constituent parts of the UK, and
some of the data used to describe today’s arrangements and to demonstrate the impact of ‘improved’
arrangements in fact drew on samples of people recruited from outside England. Although this is not ideal,
we have no reason to believe that our generalisation from England to the whole of the UK has produced
estimates that are significantly distorted.
3. METHODS: BUILDING THE MODELS
Evidence review 
We conducted a rapid review of available evidence in areas spanned by the scenarios: diagnosis, crisis
because no diagnosis has been made, evidence-based (‘improved’) care and support, and disease-modifying
treatments. Although we are particularly interested in data from and about the UK, we extended our search
to look at care improvements from the wider international context. Our search was as comprehensive as the
short timescale allowed (less than three months for the whole study). We also built on and updated a
previous review of evidence on the cost-eﬀectiveness of interventions (Knapp et al 2013). 
Modelling 
We build our approach on models previously developed in the Personal Social Services Research Unit (PSSRU)
at the London School of Economics and Political Science (LSE). Two models are used to generate estimates of
the costs and benefits of the scenarios: an aggregate model, estimating cost and quality of life impacts in one
year; and a lifetime model, estimating cost and quality of life impacts for a ‘typical’ person newly diagnosed
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with dementia. In each case we assume that care arrangements and prices are as in 2012/13, and
demographic patterns are as expected for the UK in 2015. We gross findings for England to the UK. 
The aggregate model
The dementia aggregate model estimates the costs and outcomes for all older people in England with
dementia. It is based on previous versions of the PSSRU aggregate long-term care model (Wittenberg et al
1998, 2001) and the PSSRU dementia care model (Comas-Herrera et al 2007). Figure 1 provides a simplified
representation of the model. 
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Figure 1:  Aggregate dementia model structure
Total population in England in 2015 by age and gender
Breaking down the total population by age, gender and severity of dementia (none, mild, moderate, severe)
Total costs for diﬀerent care packages by diﬀerent
types of services and severity of dementia
Splitting community population by
severity of dementia between receiving
no care, unpaid care only, formal care
only, and both formal and unpaid care
Splitting care home population by type
of setting: care home, nursing home,
hospital
Total EQ-5D scores by care packages and
severity of dementia 
Total annual costs and its components
(health, social and unpaid care costs) 
Splitting care home population by severity of dementia between receiving no
care, unpaid care only, formal care only, and both formal and unpaid care
Numbers of people by age, gender and
severity of dementia in the community
Numbers of people by age, gender and
severity of dementia in institutions ('care
homes')
Aggregation by services and severity of dementia
× 
EQ-5D scores by care packages and
severity of dementia
× 
Unit cost for diﬀerent care packages by services (health,
social or unpaid care) and severity of dementia
The model makes estimates of four key variables: number of older people with dementia, their receipt of
unpaid and formal health and social care, the costs of this care (including opportunity costs of unpaid care),
and the outcomes in terms of quality of life (measured using EQ-5D; see below). The model has four parts:
• the first divides the projected older population into cells by age, gender and severity of dementia;
• the second assigns people to diﬀerent care settings and types of care: receiving no care, unpaid care
only, formal community-based care only, both unpaid and community care, and residential care (mostly
in residential care or nursing homes but in a few cases in hospital);
• the third estimates expenditures on care by attaching to each type of care for each severity category an
average weekly cost; and
• the fourth estimates quality of life in a similar manner. 
The lifetime model
Another way to show the impact of diﬀerent scenarios is to look at a ‘typical’ older person with dementia. We
therefore also estimate the lifetime costs and outcomes for a person experiencing recent onset of dementia.
Our modelling relates to a person whose survival with dementia is 4.5 years from onset to end of life. We use
a figure of 4.5 years since Xie et al (2008) found a population-based median survival for incident dementia of
4.5 years. Our estimates should be seen as indicative of likely lifetime costs and quality-adjusted life
expectancy from onset of dementia for a person with this length of survival, which the Xie et al (2008)
findings suggest relate broadly to a person experiencing onset when aged in their eighties. It should be
noted that our estimates relate to the period from onset and not from diagnosis, which may be a
considerable time after onset.
The model divides the overall period of 4.5 years between periods with mild, moderate and severe dementia.
In some variants of scenario E in which onset or progression are delayed, the model lengthens or shortens
the period of 4.5 years in line with the scenario. It then attaches average annual costs and average annual
quality of life data to the durations in each severity state. Summing across severity states produces estimated
lifetime costs and estimated quality-adjusted life years from onset.
Sensitivity analyses 
The models inevitably require a large number of assumptions, especially as they have to draw from diﬀerent
sources and bridge gaps in the available data. At this stage we have not been able to conduct thorough
sensitivity analyses, adjusting for all plausible variations in parameter values (and certainly not combinations
thereof ), but we did carry out calculations to ensure that the cost and quality of life figures generated were
robust with respect to the key assumptions in the models. In Scenario E (disease modification) we report
estimates from a range of diﬀerent hypothetical assumptions. 
The sensitivity analyses can also provide an understanding of the relative importance of diﬀerent
assumptions, for example when the estimates from a model are much more sensitive to small changes in
some variables than in others. In principle, although not examined in this report, they can also tell us what
are perhaps some of the key drivers of cost and quality of life consequences and diﬀerences. 
Population data 
The models use the 2012-based principal population projections for England, for 2012 and 2015 (Oﬃce for
National Statistics 2013). 
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Prevalence
The models assume that the overall prevalence of dementia by age, gender and severity remains as in the
Dementia UK analyses (Knapp et al, 2007). An expert group was convened as part of that earlier study, and
considered the six high-quality British surveys available at that time (Brayne and Calloway 1989; Clarke et al
1991; Livingston et al 1990; MRC CFAS 1998; O’Connor et al 1989; Saunders et al 1993). These surveys had
been conducted in the 1980s and early 1990s and were dominated by the largest and most rigorous one,
Cognitive Functioning and Ageing Studies (CFAS I) funded by the Medical Research Council. Because of
variation in the estimates between the diﬀerent studies, a Delphi survey was conducted as part of the
Dementia UK study. A new prevalence estimate was published last year, based on a survey carried out in
England in 2008–11, referred to as CFAS II (Matthews et al 2013). This suggested that there had been a
decrease in age-adjusted prevalence (from 8.3% to 6.5% in the population aged 65 and over). 
The total prevalence estimate employed in our study is 675,000 for England, this being the figure now
assumed by the Department of Health, which we then gross up to the UK as a whole. 
The overall numbers are divided between the institutional and household population through the following
four steps:
• The estimated overall numbers of older people in care homes and hospitals are derived from the PSSRU
at LSE long-term care model.
• 57.2% of males and 73.4% of females in care homes (and in long-stay hospital care) are assumed to have
dementia, on the basis of CFAS findings.
• These numbers with dementia are then split by severity using information from the CANE trial (except
that the proportion in the severe group was assumed lower and in the moderate group slightly higher
than in CANE, to ensure that for severe dementia the care home group did not exceed the estimated total
population with severe dementia; for more information on the CANE study see Orrell et al 2007).
• The numbers in care homes are then subtracted from the overall numbers to produce estimates of the
numbers of older people with dementia living in the community. 
Patterns of care and support
We do not have up-to-date nationally representative epidemiological survey data, and so we need to
estimate how the overall prevalent population of people with dementia is distributed between diﬀerent
severity groups. We employ the usual categorisation into mild, moderate and severe, usually by reference to
MMSE data in the original datasets. 
We also need to estimate how people in each of these severity groups are distributed across diﬀerent care
settings. We distinguish five diﬀerent settings:
• no care or support, 
• unpaid care and support (only), 
• formal care and support (only) in the community, 
• both unpaid and formal care and support in the community,
• in a care home.
We have explained earlier how the numbers in care homes and long-stay hospital care are estimated. Data
from trials and some other UK sources are used to identify the patterns of care and support for each group of
people with dementia in the community, cross-categorising severity (mild, moderate, severe) and care
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setting (no care or support, unpaid care and support only, formal care and support in the community only,
both unpaid and formal care and support in the community).
Services and support data for individual people with dementia were recorded in those trials, in all but one
case using adapted versions of the Client Service Receipt Inventory (CSRI) completed by a family or
professional carer (Beecham and Knapp 2001). Coverage in those studies was comprehensive across all
services, including (but not confined to): inpatient stays, outpatient attendances, day hospital treatment,
visits to social clubs, meals at lunch clubs, day care visits, hours spent in contact with community-based
professionals such as community teams for older people, community psychologists, community psychiatrists,
general practitioners, nurses (either practice, district or community psychiatric), social workers, occupational
therapists, paid home help or care workers, and physiotherapists. Data were also collected in some studies on
support from volunteers, befriending and telephone help-line support. In all studies, information was
collected on unpaid support provided by family and friends.
We include in our dataset detailed information on about 1400 people with dementia and on more than 200
carers, collected from a dozen studies in which we had previously participated1. Consequently, much of our
data (including on quality of life) comes directly from people with dementia or from carers. From the trials we
use (retrospective) baseline data only (for both intervention and control groups). We first categorise everyone
from the trials by severity and settings (e.g. formal only, unpaid care only etc.) and then exclude all people in
severity/setting combinations that are in conflict with the exclusion/inclusion criteria for the trial. For
example, some people in a trial of a carer intervention were recorded as ‘formal care only’, yet we knew that
these people needed to have an unpaid carer to be included in the study. In another study of cognitive
stimulation therapy for people with mild or moderate cognitive impairment we found a few people with
severe dementia.
Data on hours of unpaid care provided by carers are available for co-resident and non-co-resident carers, and
these are totalled. In some studies, co-resident carers had been asked to estimate the percentage of time
they could spend away from the person with dementia (e.g. 0–25%, 25%–50%), and we take mid-points of
these ranges and convert them into hours (assuming a waking day of 16 hours). 
Costs
The service use data collected in the individual studies noted above are converted to cost estimates. The
studies from which data were drawn had used unit costs that reflect reasonably well long-run marginal
opportunity costs, and generally came from sources in the public domain – mainly from the PSSRU volume
(Curtis 2013) and the National Health Service Schedule of Reference Costs (for inpatient and outpatient
costs). All costs are inflated to 2012/13 prices.
The costs are those of the total care and support used, not just those that can be directly attributed to
dementia. It is not possible with the data available for this study to separate costs associated with treatment
and care of dementia from those associated with treatment and care linked to other health or social care
needs. Indeed, in a clinical context it would often be extremely diﬃcult to separate the reasons for particular
treatments and care arrangements. In a study with better data and more time, it would be possible to use
multivariate statistical techniques to try to tease out the relative contributions of dementia and other
conditions.
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1. These studies were SADD (Banerjee et al 2011,; Romeo et al 2013), some component studies within the SHIELD
programme (Orrell et al 2014; D’Amico et al 2014; unpublished CSP data), DADE (Lacey et al 2012; Trigg et al 2014),
EVIDEM (Lowery et al 2013; unpublished cost data), LASER-D (Livingston et al 2008), DOMINO (Howard et al 2012 for QOL
data), CST (Spector et al 2003; Knapp et al 2006), CANE (Orrell et al 2007) and START (Livingston et al 2013; Knapp et al
2013).
It is notoriously diﬃcult to estimate the number of hours spent by carers in the support of a relative or friend
with dementia. Some of the time devoted by carers is taken up with hands-on care, some of it with
‘supervision’ to ensure that nothing untoward occurs. Our estimates are based upon time reported by carers
in the various trials and other studies, using a fairly consistent wording in the interview schedules. We attach
to each hour of self-reported unpaid care a cost that is approximated by the national minimum wage in
England as an indication of the opportunity cost. Again, this is an area of diﬃculty, indeed sometimes
controversy. Some imputations of the cost of unpaid care have used a higher hourly rate, such as the cost of
substituting the unpaid care of family members with a home care worker employed by a health or social care
agency. Clearly the assumptions made about the number of hours of unpaid care and the associated cost will
work through to influence the cost of any scenario and therefore the comparative cost of alternative
approaches to dementia care.
We are not able to include costs of services used by carers which might be associated with the strain of
providing unpaid care. The primary reason for that exclusion is the paucity of data. However, in looking at
one of the variants of the improved care scenario (a coping strategy for carers) we discuss the consequences
for their use of services. 
Expenditure breakdown by source
Health care costs are assumed to be met entirely by the NHS. Social care costs would be met partly by local
authorities (municipalities) and partly by people with dementia themselves, either through self-funding their
care or through user charges, but we have not split these costs. The costs of unpaid care fall to the carers,
although they may receive social security benefits (especially Carers Allowance) and/or social services
support in recognition of their caring role. 
Quality of life and QALYs
Quality of life is estimated from data collected in the trials and other studies using the EQ-5D (EuroQol Group
1990). This measure is widely used in the UK and many other countries to provide a generic summary (valid
across diﬀerent disease areas) of the impact on quality of life. EQ-5D has five dimensions of health-related
quality of life: mobility, self-care, usual activities, pain/discomfort, and anxiety and depression. It is not a
dementia-specific scale, and is therefore perhaps less sensitive to the experiences of people with dementia
than we would like. (A tool such as the DEMQOL (Smith et al 2007) would have been preferable but has not
been widely used until recently, and we had more data for the EQ-5D.) We applied societal weights (the York
A1 Tariﬀ; Dolan et al 1995) to the 243 possible health states obtained from the EQ-5D by combining ratings
on the five domains to calculate utility values. Quality-adjusted life years (QALYs) were calculated by ‘area
under the curve’ analysis, with linear interpolation between assessment points.
We use self-reported EQ-5D values for people with dementia. We do not combine this self-reported and
proxy-reported EQ-5D.2 We have some data from the trials on carer quality of life (again using EQ-5D, self-
reported), but have not been able to model quantitatively the impact of diﬀerent scenarios on the quality of
life of carers. Relatively few studies have collected data that would allow such examination. We do, however,
comment on carer quality of life implications of diﬀerent assumptions, and refer to previous estimates of
these impacts where they are available. 
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2. There was one exception. From the DADE study for people with severe dementia we only have proxy EQ-5D scores. To
estimate self-reported EQ5D scores (to be consistent with the other studies), we ran a regression for the subsample of the
DADE study with mild or moderate dementia (for whom we had both self-report and proxy EQ5D scores). We regressed
self-reported EQ-5D score as the dependent variable and the proxy score as an independent variable, along with a
number of covariates: age, gender, whether or not the spouse was the main carer and the time (in years) since diagnosis
of dementia. We then extrapolate to the group with severe dementia.
4. OPERATIONALISING THE SCENARIOS
These scenarios have not been previously studied or compared in the way that we are doing in this study,
and so the evidence base from which we build our estimates is far from ideal. We therefore use a range of
modelling techniques to examine the economic implications of diﬀerent care and support arrangements,
and extract data from a wide range of sources, including epidemiological studies, descriptions of patterns of
care and support, randomised trials of specific interventions and expert opinion. Costs and quality of life
gains are estimated by bringing together data from a dozen recent UK dementia trials and observational
studies. 
We operationalise Scenarios B and C and the four variants of Scenario D by moving people between severity
categories and types of care, by amending the average weekly costs of care and by adding or subtracting the
costs of diagnoses, medication and other interventions. We operationalise the variants of Scenario E by using
amended prevalence rates of dementia to reflect delayed onset or delayed progression and by reducing the
average weekly costs of care in some variants. 
The current care scenario (Scenario A) 
Under this first scenario, people with dementia and their carers receive care and support as currently
provided in England in 2012, with numbers ‘up-rated’ to the population projected for the UK for 2015. We
include the following services and costs for the current system:
• diagnoses for the 50% of people with dementia who currently receive a diagnosis;
• assessment and reviews and care management on the basis that around one third of the total national
costs as recorded in oﬃcial local authority returns relate to people with dementia;
• medications for the estimated 15% of people with dementia who receive them, on the basis that the
costs of medications are included in the costs reported in the trials;
• care home fees, at an estimated £500 per week for those in residential care homes and £600 per week for
those in nursing homes;
• unpaid and formal care provided to people in care homes from outside their care home, as reported in
the trials (baseline data, that is before randomisation);
• hospital care for the small numbers assumed to have a hospital as their primary residence, in accordance
with data from the trials;
• unpaid and formal care for people with dementia living in the community, on the basis of data from the
trials. 
The no-diagnosis scenario (Scenario B)
In this second scenario, people with dementia do not have their condition diagnosed and so do not receive
dementia-specific care. We sought to operationalise this scenario by looking at three possibilities: (a) people
with dementia no longer have access to medications that alleviate the symptoms of dementia; (b) dementia-
specific community-based social care is no longer provided; and (c) crises occur. We assume that nobody has
a diagnosis, and therefore the cost of the diagnosis itself is saved.
For the first of these three possibilities we take data on the eﬀect of taking donepezil on cognitive
impairment (measured by MMSE score) as reported by Bond et al (2012) and Howard et al (2012). We assume
that 20% of people with mild or moderate cognitive impairment are currently taking donezepil or another
dementia medication (117,600 people). There are of course a number of medications now used specifically to
treat people with dementia. We have assumed for simplicity that patients are treated with donepezil only.
This assumption is made purely to keep the modelling manageable, given the short timescale for this work.
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Donepezil is now oﬀ patent in the UK, and the cost we assume in our calculations is the cost for the generic
drug. The eﬀect of donepezil on cognition is suggested to be on average 1.2 MMSE points over 6 months
(Bond et al 2012) and 1.7 MMSE points over 12 months (Howard et al 2012). We use these trial-based findings
to estimate the numbers of people with Alzheimer’s disease who, because they would not be taking this
medication, would be in a higher severity group, assuming a uniform distribution of people across MMSE
scores within each severity group. Health care costs are reduced because of decreased spending on
medications (£4.4 million over one year), although may increase in other areas. 
For the second possibility, where dementia-specific community-based social care is no longer provided, we
assume that this would only aﬀect people who receive both formal and unpaid care in the community and
have no ADL needs. We use estimates from CFAS I (MRC CFAS 1998) on the proportion of users of formal
community care with cognitive impairment but no ADLs (average 16% across both genders). We assume that
these 16% receiving unpaid and formal care would stop receiving it: those in the mild and moderate
categories would move to a situation where they were receiving unpaid care only, and those in the severe
category would move to care homes. Among those receiving both unpaid and formal care, social care unit
costs are reduced by multiplying by 0.7 (due to lower use of services such as day care and respite care) and
unpaid care is multiplied by 1.5 to reflect the greater number of hours now needed. Health care costs are
increased by an amount equal to a proportion of the reduction in social care unit costs (reflecting Fernandez
and Forder 2008). We also assume a decrease in social care assessments proportional to the decrease in social
care users.
The third possibility is that crises will occur because dementia is not identified or treated. We are not able to
find quantitative estimates of the impact, although consultation with a number of experts in the field
identified quite a range of possible negative consequences, including higher risks of fires, gas explosions,
domestic flooding, physical illness (as people do not take their medications and do not present with
problems), self-neglect and weight loss (leading to falls and physical illness), unclaimed pensions (leading to
problems with not paying bills, and so services could be cut oﬀ and there could be eviction threats), getting
lost (exposure, hospital admission), vulnerability (money stolen, abuse), family breakdown, eviction for
antisocial behaviour, disinhibition, and neglect for someone they are caring for. There could be worsening of
quality of life for family members. These are potentially important impacts but we are not able to include
them in our modelling. 
The diagnosis-only scenario (Scenario C)
In our third scenario, people with dementia receive a diagnosis (mean cost £650; Dixon et al 2014), but get no
(dementia-specific) post-diagnostic formal care or treatment. This is identical to Scenario B except that we
now add a cost for diagnosis, which we assume is conducted in a memory clinic and not in primary care. We
assume that all incident dementia cases get a diagnosis, and not the people who were previously diagnosed
(prior to the year under study). We do not add a cost for people who would have been assessed in a memory
clinic but who did not then receive a diagnosis of dementia (i.e., we do not factor in how many people need
to be assessed in order to identify all incident dementia cases), and so we are under-estimating the cost of
this scenario. 
We are not taking into account any decrement to quality of life – for the person with dementia or their family
– that might follow from having a diagnosis but then receiving no post-diagnostic care. 
The improved care scenarios (Scenario D)
The next scenario describes a situation where people with dementia receive a diagnosis, followed by
evidence-based, ‘improved’ care and support, where ‘improvements’ have been demonstrated in robust trials.
In selecting which ‘improvements’ to model we have been guided by recommendations from the National
Institute for Health and Care Excellence (NICE). These include: post-diagnostic support and care
management; cognitive stimulation for all those with mild to moderate dementia; acetylcholinesterase
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(AChE) inhibitors (donezepil, galantamine and rivastigmine for mild to moderate Alzheimer's disease) and
memantine (an option for people with moderate Alzheimer's who are intolerant or have contraindication to
AChE inhibitors, or severe AD); assessment of non-cognitive symptoms and behaviour that challenges (but
no specific recommendations regarding treatment); the same access to palliative care and end of life care as
the rest of the population; assessment of carers' needs; carer support interventions; and respite/short-break
services, including day care, day and night sitting, adult placement and short-term or overnight placement in
residential care. 
In operationalising Scenario D, we are only able to look at a subset of the elements recommended by NICE
because of data limitations. We also look at these possible improvements to care and support arrangements
one by one rather than in combination, because available evidence does not tell us how the quality of life or
cost impacts would ‘stack up’ if more than one of these improvements was introduced simultaneously. We
assume 100% coverage following diagnosis. 
We model four components of this ‘improved care’ scenario.
The first (called D1) assumes that everyone with Alzheimer’s disease receives donepezil. We previously set out
the processes used to generate estimates of cost and quality of life impacts when describing Scenario B
(although now applied in reverse), and our main sources for the eﬀectiveness evidence are the meta-analysis
and model of Bond et al (2012) and the DOMINO trial for people with more severe dementia (Howard et al
2012). This improvement will increase health care costs in so far as more medications will be prescribed, but it
slows disease progression, and so – in our model – alters the distribution of people across severity categories
and care settings.
The second component (D2) assumes that everybody receives cognitive stimulation therapy (CST) in the mild
or moderate state. CST is usually delivered over 7 weeks and has been shown to be eﬀective and cost-
eﬀective (Spector et al 2003; Knapp et al 2006; Woods et al 2012). A recent trial shows that it is also eﬀective
and cost-eﬀective over a further 16-week period as ‘maintenance’ therapy (Orrell et al 2014, D’Amico et al
2014). We assume from these trials that the eﬀect of standard CST is to slow cognitive decline by 0.6 MMSE
points over one year. The trials show that the intervention is likely to be cost-neutral in so far as the cost of
intervention is compensated by decreased intensity of use of services, although there will be a shift in the
distribution of costs between categories.
The third component that we look at is case management (D3). We were given early sight of a forthcoming
Cochrane Review by Reilly et al (2014). Although this review awaits final sign-oﬀ, its conclusions suggest that
case management reduces the likelihood of institutionalisation (which we interpret in the terms of our model
as admission to a care home), although the findings over successive time periods are not unambiguous. Reilly
et al (2014) do not find evidence of significant quality of life benefits for people with dementia or for carers.
We assume that all older people newly experiencing onset of dementia receive a diagnosis, and that those
with mild or moderate dementia living in the community are given (extra) case management at an assumed
annual cost of £500 per person. The number of people with moderate or severe dementia living in a care
home is estimated to reduce by 27.5% as a result of this intervention. 
Finally we look at the support provided to carers (D4). The START study evaluated a coping strategy for carers
and found significant eﬀectiveness and cost-eﬀectiveness gains over the 8-month period following the
receipt of the intervention (Livingston et al 2013; Knapp et al 2013). We do not include carer service use costs
or carer quality of life in our model because – generally across the various trials and other sources – we are
not able to find suﬃcient data. However, the START study found that savings in carers’ use of health services
(£67 per carer over the evaluation period) partly oﬀset the cost of the intervention itself (£232 per carer). If
this kind of intervention were to reduce the likelihood of care home admission in the longer term – and we
have made that assumption for the purposes of our modelling – then that would potentially aﬀect both the
quality of life of the person with dementia and the costs of their care. We assume that all older people newly
experiencing onset of dementia receive a diagnosis, and that the carers of those with mild or moderate
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dementia living in the community are given (extra) carer support. The number of people with moderate or
severe dementia living in a care home is assumed to reduce by 5% as a result of the intervention. 
The disease-modifying scenario (Scenario E)
In our final scenario we examine the impact of one or more disease-modifying treatments being available,
either to slow the progression of dementia or to delay its onset. We assume that all people with onset of
dementia receive a diagnosis, and then that all receive the disease-modifying treatment at least while in the
mild or moderate severity state. For the delayed-onset variants, the treatment might need to be prescribed
more widely, for example to all older people thought to be at high risk of onset of dementia, although we do
not cost that possibility in our models. 
In calculating consequences for cost and quality of life, we assume that the disease-modifying treatments are
already available, indeed have been available for a while. Unlike the analyses in another study that has very
recently been completed by the Oﬃce of Health Economics (Lewis et al 2014), we are not looking at the
impact of phasing in a disease-modifying treatment over a period of time, but assume that a steady state of
availability has already been achieved. 
We can make diﬀerent assumptions about the cost of this new treatment itself. In Section 5 we show the
impacts of a disease-modifying treatment under a range of diﬀerent ‘price’ assumptions. 
The nature and details of the five variants are outlined in Table 1 below. For delayed progression we assume
10% longer duration in the mild state and 10% longer duration in the moderate state. Scenarios E1 and E2
diﬀer in terms of whether mortality rates rise in the severe state, holding survival from onset constant, or
whether mortality rates in the severe state are unchanged, increasing overall survival from onset. Scenario E3
considers a case where the treatment reduces average levels of need within the mild and moderate states,
allowing average weekly costs to fall. Scenarios E4 and E5 relate to delayed onset of dementia of one and
three years respectively.
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Table 1: Description of Scenario E variants
Scenario Severity prevalence Cost by severity and care type
E1. Progression delayed: 10% longer in
mild state and 10% longer in moderate
state; mortality in severe state rises,
keeping overall survival constant 
Increased prevalence in mild and
moderate states; greatly reduced
prevalence in severe state 
No change by severity state and
type of care
E2. Progression delayed: 10% longer in
mild state and 10% longer in moderate
state; mortality rate in severe state does
not rise, increasing survival 
Increased prevalence in mild and
moderate states; marginally reduced
prevalence in severe state 
No change by severity state and
type of care
E3. Progression delayed: 10% longer in
mild state and 10% longer in moderate
state; mortality rate in severe state does
not rise, increasing survival
Increased prevalence in mild and
moderate states; marginally reduced
prevalence in severe state 
Average weekly costs of
community care in mild and
moderate groups reduced by
13.5% (see Results section)
E4. Onset of dementia delayed by one
year
Reduced prevalence rates in all states:
rate for age 75 applied to age 76 (etc.) 
No change by severity state and
type of care
E5. Onset of dementia delayed by three
years
Reduced prevalence rates in all states:
rate for age 75 applied to age 78 (etc.)
No change by severity state and
type of care
5. RESULTS 
We estimate that there are around 800,000 older people with dementia in the UK. It should be noted that this
excludes the relatively small number of people aged under 65 with early onset dementia. The total comprises
around 440,000 people with mild dementia (MMSE 26 to 21), 260,000 with moderate dementia (MMSE 20 to
10), and 100,000 with severe dementia (MMSE under 10). 
We estimate that around 225,000 older people in the UK will experience onset of dementia in 2015. The ratio
of the numbers with dementia to this estimate of new cases might suggest that average survival of older
people from onset of dementia is less than 4 years. However, this would be an under-estimate since the
numbers of new cases of dementia have likely been rising as the overall numbers of older people have been
increasing.
There are around 285,000 older people with dementia in care homes in the UK and an assumed 8,000 whose
primary residence is a hospital. Of the remaining 510,000 people with dementia, we expect, on the basis of
evidence from the trials, that some 85,000 receive no care, 85,000 receive unpaid care only, 130,000 receive
formal care services only and 210,000 receive both unpaid and formal care.
Our analyses suggest that the cost of dementia among older people in the UK is approximately £21 billon (at
2012/3 prices). This comprises around £4,150 million health care costs, £9,550 million social care costs
(publicly and privately funded) and £7,450 million implicit cost of unpaid care. This amounts to 20% health
care, 45% social care (publicly and privately funded) and 35% unpaid care. (The cost of unpaid care is
calculated at national minimum wage for time inputs reported by carers.) This figure of £21 billion is likely an
under-estimate, and we will be revisiting this figure in work funded by the Alzheimer’s Society which will be
reported later in 2014.
We estimate that under current patterns of care the lifetime cost of care is around £125,000 over a period of
4.5 years from onset of dementia in a person’s eighties to end of life, and that the quality-adjusted life
expectancy is around 3.55 years from onset. These estimates should be treated with great caution.
Impact of Scenarios B and C
Scenarios B and C, while not aﬀecting the overall number of older people with dementia, would lead to an
increase in the proportions with moderate and severe dementia. Scenario B would be around £350 million
more costly than the current pattern of care (Scenario A), and Scenario C would be around £500 million more
costly. Outcomes would be slightly lower. 
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Table 2: Annual costs for current care and support, no-diagnosis and diagnosis-only (Scenarios A, B, C)
ANNUAL COSTS IN 2015 (£, millions, 2012 prices, UK)
VARIANTS OF THE SCENARIO Health care Social care Unpaid care Total
Current care and support (Scenario A) 4,150 9,550 7,470 21,160 
No-diagnosis scenario (Scenario B) 4,190 9,970 7,350 21,510 
Diagnosis-only scenario (Scenario C) 4,330 9,970 7,350 21,650 
Impact of Scenario D
The four variants of Scenario D would also not aﬀect the overall number of older people with dementia, but
D1 (medication) and D2 (cognitive stimulation therapy) would lead to an increase in the proportion with mild
dementia. The costs of these scenarios are set out in Table 3. Relative to current patterns of care, the
diﬀerences would be: D1 around £250 million less costly, D2 broadly the same cost, D3 (case management)
around £225 million more costly and D4 (carer support) around £200 million more costly.
The estimated impact on outcomes of these scenarios is modest. That may be partly because we have used a
relatively crude measure (QALYs generated from the generic EQ-5D) and did not look at symptom alleviation
or other more clinical measures. The modest impact is certainly partly a consequence of limitations in the
data available for our modelling, and because our modelling is not able to take into account changes in
quality of life (or indeed costs) within severity-setting cells. Nor are we measuring the eﬀects on carer quality
of life, which is, for example, an important gain found in the START study by Livingston et al (2013). A further
consideration is that careful targeting of the interventions on those individuals most likely to benefit from
them – if it was possible to identify such individuals – would be likely both to improve outcomes and to
reduce costs. More work is required to explore the outcomes in a more refined manner than was possible
within the time available for this study. 
We should emphasise that we have examined these four scenarios independently of one another, and have
not attempted to aggregate the cost and outcome impacts. There is no reason why the four interventions
modelled under Scenario D should not be delivered together, but we have no way of estimating whether the
combined eﬀect would be a simple addition of the individual eﬀects. (Orrell et al, 2014, show that there can
be added benefits of combining cognitive stimulation therapy and acetylcholinesterase inhibitor
medications.)3
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Table 3: Annual costs for base case and improved care scenarios
ANNUAL COSTS IN 2015 (£, millions, 2012 prices, UK)
VARIANTS OF THE SCENARIO Health care Social care Unpaid care Total
Current care and support 
(Scenario A)
4,150 9,550 7,470 21,160
Improved care: donepezil 
(Scenario D1)
4,140 9,160 7,620 20,920
Improved care: cognitive stimulation
(Scenario D2)
4,300 9,340 7,530 21,160
Improved care: case management
(Scenario D3)
4,060 8,480 8,840 21,380
Improved care: carer support 
(Scenario D4)
4,200 9,310 7,850 21,370
3. A more ambitious study is currently underway that will provide a more robust platform of models than possible here,
and therefore more robust estimates of cost, quality of life and other outcome consequences. At the 2013 Dementia
Summit, the UK Government announced new research studies, one of which (led from the LSE) has recently started, and
will allow more detailed modelling of future costs and outcomes for diﬀerent care and support arrangements for
dementia. This is the MODEM study: ‘A comprehensive approach to modelling outcome and cost impacts of interventions
for dementia. It is funded by the ESRC and NIHR. The MODEM study is developing a comprehensive, integrated,
quantitative set of models to estimate current and future needs, and the outcomes and costs of interventions aimed at
meeting them. It will be completed in early 2018. Please contact Adelina Comas-Herrera (a.comas@lse.ac.uk) for details.
Impact of Scenario E 
Scenarios E1 to E3 relate to delayed progression of dementia from mild to moderate states, and from
moderate to severe states, but with no delay in initial onset. Our cost findings are set out in Table 4. E1 is
almost £800 million cheaper than current patterns of care (Scenario A) and would produce slightly better
outcomes. This is because there would be only some 32,000 people with severe dementia in comparison with
slightly over 100,000 at present. The scenario does however assume that the mortality rate in the severe state
would be higher than currently, such that overall survival with dementia would not rise.
Scenario E2 is similar to E1 but assumes that the mortality rate for severe dementia would not rise and
instead survival would rise, by around 0.35 years. The number of people with dementia would be 870,000
rather than 800,000, the cost would be £1,725 million higher than under current patterns of care, and
outcomes would be noticeably. We estimate that the lifetime cost of care would be around £135,000 over a
period of 4.85 years, in comparison with £125,000 over 4.5 years under current patterns of care. There would
be a gain of about 0.31 quality-adjusted life years per person over this period. These estimates should be
treated with great caution. 
E3 is similar to E2 but assumes that the average weekly cost of community-based care (formal and unpaid) for
people with mild or moderate dementia would be lower than at present. This is on the basis that the new
treatment might reduce average levels of need within the mild and moderate severity states as well as
prolonging their duration. A fall of around 13.5% in weekly costs renders this scenario broadly cost-neutral in
comparison with current arrangements before considering the cost of the new treatment itself. The number
of people with dementia would again be 870,000 rather than 800,000, the cost would be only £125 million
higher than currently, and outcomes would be the same as for E2. The estimated lifetime cost would be
similar to the current system but survival and quality-adjusted life years from onset would be as per Scenario
E2. 
Scenarios E4 and E5 assume delays to the onset of dementia by one year and three years respectively, with
progression after onset unchanged from what happens at present. The estimated numbers of people with
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Table 4: Annual costs for base case and disease modifying scenarios
ANNUAL COSTS IN 2015 (£, millions, 2012 prices, UK)
VARIANTS OF THE SCENARIO Health care Social care Unpaid care Total
Current care and support (Scenario A) 4,150 9,550 7,470 21,160 
Slowed progression, life expectancy
unchanged (E1)
3,920 8,480 7,970 20,370
Slowed progression, life expectancy
increased (E2)
4,520 10,190 8,180 22,890
Slowed progression, life expectancy
increased, weekly costs reduced (E3)
4,190 9,930 7,170 21,280
Delayed onset by 1 year (E4) 3,910 8,850 6,900 19,660
Delayed onset by 3 years (E5) 3,240 7,360 5,650 16,250
Note: Some figures might not add up due to rounding
dementia would be around 740,000 and 610,000 respectively, rather than the present 800,000. Costs would
be £1.5 billion lower (7% of current cost) for E4 and £4.9 billion lower (23% of current cost) for E5 than under
current patterns of care. Lifetime costs would be somewhat lower than at present for E4 and more
substantially lower for E5, since survival with dementia would be lower from later onset. There would be
quality-adjusted life year gains from both scenarios, particularly E5.
We have not included a cost for the disease-modifying treatment itself, and the figures in Table 4 assume that
the treatment would be free to purchase or deliver. If the cost was £100 per patient year, then the annual cost
of delivery for Scenarios E1, E2 and E3 would be £75 million across the UK as a whole, and if the annual cost
per patient was £1,000 the total bill would be £750 million, which would seriously eat into any savings
elsewhere in the health and social care systems. For scenarios E4 and E5, the treatment cost would depend
on how many older people needed to be oﬀered (and then accepted) the new medication to ensure that the
average delayed onset of one year or three years could be achieved.
6. CONCLUSIONS
In December 2013, Health Ministers from the G8 countries and the UK Prime Minister met in London for a
Dementia Summit, and subsequently issued both a Declaration and a Communique. These two documents
spelt out clearly the challenges so often experienced by people living with dementia, their families and other
carers, and emphasised the need for concerted action in many domains. Central to national or international
eﬀorts to improve the lives of people with dementia and other carers must be timely diagnosis followed by
appropriate treatment, care and support. Also central to such eﬀorts must be the search for ways to prevent
or slow down the progression of dementia. 
We have shown that evidence-based care and support interventions are available that improve the quality of
life of older people with dementia and their carers. They would not cost very much more to oﬀer to larger
numbers of people than is currently the case. If it was possible to target those interventions on people with
dementia and carers for whom the benefits are most likely to be achieved then this would also help to bring
down the overall costs. A word of caution is important here: some of the scenarios would result in a shift of
cost from formal services to unpaid carers (i.e. would require family and other carers to provide more unpaid
hours of support). The availability and willingness of carers to oﬀer this greater increased supply must be
considered. 
We have also shown that to reduce the costs of care and support in more than a small way will require the
development of new interventions. It may be that new ways to deliver care and support currently being
introduced but not yet evaluated would oﬀer important cost or outcome gains, and it is very important that
the search continues until such time as a disease-modifying treatment becomes available. However, on the
basis of our (hypothetical) calculations, it will take a treatment that delays dementia onset to substantially
alter the level of costs. Such a treatment would lead to a reduction – or at least a slower increase – in the
numbers of people with dementia and therefore in the costs of caring for them, while also improving quality
of life. Medication that delayed the progression of dementia from the mild to the moderate and severe stages
could reduce, or at least slow the increase in, numbers of people with dementia and/or increase overall
survival with dementia, but with smaller impacts on cost. 
The figures from our analyses show clearly the need for a two-pronged response to the economic challenge
of dementia. We need to continue to invest in treatment, care and support that can improve the lives of
people with dementia and their carers, both now and over the coming years. Those interventions may not
significantly reduce the overall costs of care, but could significantly improve quality of life. The second prong
is to continue to invest in basic and clinical research to find disease-modifying treatments. The latter strategy
oﬀers the best hope for an aﬀordable and eﬀective response to rapidly growing global needs.
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